NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
This study confirmed that evidence was lacking about the optimal mode of delivery for women in preterm labour and found agreement that a trial should be conducted.
Abstract
Background:
Around 60,000 babies are born preterm (prior to 37 weeks’ gestation) each year in the UK. There is little evidence on the optimal birth mode (vaginal or caesarean section).
Objective:
The overall aim of the CASSAVA project was to determine if a trial to define the optimal mode of preterm birth could be carried out and, if so, determine what sort of trial could be conducted and how it could best be performed. We aimed to determine the specific groups of preterm women and babies for whom there are uncertainties about the best planned mode of birth, and if there would be willingness to recruit to, and participate in, a randomised trial to address some, but not all, of these uncertainties. This project was conducted in response to a Heath Technology Assessment programme commissioning call (17/22 ‘Mode of delivery for preterm infants’).
Methods:
We conducted clinician and patient surveys (n = 224 and n = 379, respectively) to identify current practice and opinion, and a consensus survey and Delphi workshop (n = 76 and n = 22 participants, respectively) to inform the design of a hypothetical clinical trial. The protocol for this clinical trial/vignette was used in telephone interviews with clinicians (n = 24) and in focus groups with potential participants (n = 13).
Results:
Planned sample size and data saturation was achieved for all groups except for focus groups with participants, as this had to be curtailed because of the COVID-19 pandemic and data saturation was not achieved. There was broad agreement from parents and health-care professionals that a trial is needed. The clinician survey demonstrated a variety of practice and opinion. The parent survey suggested that women and their families generally preferred vaginal birth at later gestations and caesarean section for preterm infants. The interactive workshop and Delphi consensus process confirmed the need for more evidence (hence the case for a trial) and provided rich information on what a future trial should entail. It was agreed that any trial should address the areas with most uncertainty, including the management of women at 26–32 weeks’ gestation, with either spontaneous preterm labour (cephalic presentation) or where preterm birth was medically indicated. Clear themes around the challenges inherent in conducting any trial emerged, including the concept of equipoise itself. Specific issues were as follows: different clinicians and participants would be in equipoise for each clinical scenario, effective conduct of the trial would require appropriate resources and expertise within the hospital conducting the trial, potential participants would welcome information on the trial well before the onset of labour and minority ethnic groups would require tailored approaches.
Conclusion:
Given the lack of evidence and the variation of practice and opinion in this area, and having listened to clinicians and potential participants, we conclude that a trial should be conducted and the outlined challenges resolved.
Future work:
The CASSAVA project could be used to inform the design of a randomised trial and indicates how such a trial could be carried out. Any future trial would benefit from a pilot with qualitative input and a study within a trial to inform optimal recruitment.
Limitations:
Certainty that a trial could be conducted can be determined only when it is attempted.
Trial registration:
Current Controlled Trials ISRCTN12295730.
Funding:
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 61. See the NIHR Journals Library website for further project information.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Introduction
- Chapter 2. Study design
- Chapter 3. The clinician survey
- Chapter 4. The public opinion survey
- Chapter 5. The Delphi survey
- Chapter 6. Development of a short trial protocol
- Chapter 7. Qualitative research
- Chapter 8. Conclusions
- Acknowledgements
- References
- Appendix 1. Updated search strategy and outputs from relevant papers to inform the Delphi survey
- Appendix 2. Examples of comments from the Delphi survey
- Appendix 3. Summary hypothetical trial protocol
- Appendix 4. Full hypothetical trial protocol
- List of abbreviations
- List of supplementary material
About the Series
Declared competing interests of authors: Jane E Norman has received grants from government and charitable bodies for research into understanding the mechanisms of term and preterm labour and understanding treatments, including research funding from the National Institute for Health Research (NIHR) (references 17/63/08 and 16/151/01). Within the last 3 years, Jane E Norman has acted on a Data Safety and Monitoring Board for a study involving a preterm birth therapeutic agent for GlaxoSmithKline plc (Brentford, UK) and has provided consultancy for a small pharma company on drugs to alter labour progress. In addition, Jane E Norman was a member of the Health Technology Assessment (HTA) Maternal Neonatal and Child Health Panel (2013–18) and was a member of the HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board from 2012 to 2014. Julia Lawton was a member of HTA Obesity Themed Call Board (2010) and HTA General Committee (2018–19). Sarah J Stock reports grants from the NIHR HTA programme during the conduct of the study and declares being a member of the NIHR HTA General Committee (2016–21). In addition, Sarah J Stock received other research funding from the NIHR (reference 14/32/01), Wellcome Trust (London, UK) (reference 209560/Z/17/Z) and Chief Scientist Office (London, UK) during the course of the study. Dimitrios Siassakos reports grants from the NIHR HTA Research for Patient Benefit (reference PB-PG-0817-20046) and HTA programme (references 16/16/06, NIHR127818 and PR-PRU-1217-21202) during the conduct of the study. In addition, Dimitrios Siassakos reports grants from the NIHR Biomedical Research Centre at University College London Hospitals (London, UK) and non-financial support from Wellcome Engineering and Physical Sciences Research Council Centre for Interventional and Surgical Sciences (London, UK) outside the submitted work. Last, Dimitrios Siassakos was a member of the HTA Maternal, Neonatal and Child Health Panel (2017–18), HTA Prioritisation Committee C (Mental Health, Women and Children’s Health) (2017–20) and HTA Prioritisation Committee B (In Hospital) (2017–21). John Norrie reports grants from the University of Edinburgh (Edinburgh, UK) during the conduct of the study, and is a past and present member of the following: HTA Commissioning Sub-Board (Expressions of Interest) (2012–16), NIHR Clinical Trials Unit Standing Advisory Committee (2017–present), NIHR HTA and EME Editorial Boards (2014–19), Pre-Exposure Prophylaxis Impact Review Panel (2017–present), EME Strategy Advisory Committee (2019–present), EME – Funding Committee Members (2019–present), EME Funding Committee Sub-Group Remit and Competitiveness Check (2019–present), HTA General Committee (2016–19), HTA Funding Committee Policy Group (formerly Clinical Study Group) (2016–19) and HTA Commissioning Committee (2010–16). In addition, John Norrie acted as a NIHR Journals Library Editor between 2014 and 2019. Nina Hallowell is a member of the Wellcome Centre for Ethics and Humanities (Oxford, UK), which is supported by funding from the Wellcome Trust (grant number 203132).
Article history
The research reported in this issue of the journal was funded by the HTA programme as project number 17/22/02. The contractual start date was in November 2018. The draft report began editorial review in January 2021 and was accepted for publication in June 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Disclaimer
This report contains transcripts of interviews conducted in the course of the research and contains language that may offend some readers.
Last reviewed: January 2021; Accepted: June 2021.
- NLM CatalogRelated NLM Catalog Entries
- Feasibility and design of a trial regarding the optimal mode of delivery for pre...Feasibility and design of a trial regarding the optimal mode of delivery for preterm birth: the CASSAVA multiple methods study
- Carer administration of as-needed subcutaneous medication for breakthrough sympt...Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT
- A pilot randomised trial to assess the methods and procedures for evaluating the...A pilot randomised trial to assess the methods and procedures for evaluating the clinical effectiveness and cost-effectiveness of Exercise Assisted Reduction then Stop (EARS) among disadvantaged smokers
Your browsing activity is empty.
Activity recording is turned off.
See more...